In recent issues of Critical Care, we read with concern the article by Pontes-Arruda and colleagues [1] and the fi rst author's reply to the letter from Machado (the latter two of which appear in [2] ). Th e article and subsequent letters address eicosapentaenoic acid/gamma-linolenic acid (EPA/GLA) use in sepsis patients in the INTERSEPT (Investigating Nutritional Th erapy with EPA, GLA and Antioxidants Role in Sepsis Treatment) study.
We served as the principal investigators of this trial and come from sites that did not successfully include any patients or that included only a small number of patients. From this vantage point, we believe that Pontes-Arruda's reply to Machado's comments [2] did not clarify several important points.
As stated in the article [1] , only fi ve of the 12 sites successfully enrolled patients. However, the fi rst author's site was responsible for the inclusion of about 100 of the 106 patients. We believe that this imbalance is relevant and that readers of Critical Care need to be aware of it. We disagree with Pontes-Arruda's response [2] that all relevant limitations were already mentioned in the Discussion [1] . We found it diffi cult to understand his affi rmation that the results were unaff ected by the unbalanced distribution pattern of the patients, as any statistical analysis of the few patients from the other four sites would obviously be under powered. We also think he should clearly state the strategies that were used at his site to successfully enroll patients given that the 11 other sites, most of which are very skilled at performing intervention studies, failed to enroll similar numbers of patients.
Th e author's explanation [2] of the Sequential Organ Failure Assessment (SOFA) fi ndings is also not clear. We agree that it is perfectly possible for some patients to have a high SOFA score that may be insuffi cient to fulfi ll the inclusion criteria. However, the median and inter quartile values shown in Table 3 [1] indicate that 75% of all patients had a SOFA score of more than 4. Th is would be a very unusual fi nding in sepsis patients without signifi cant organ dysfunction. Moreover, the interquartile interval in Table 3 indicates that at least 75% of the patients had platelet levels of more than 144 × 10 9 cells per liter, a bilirubin level of less than 1.5 mg/dL, and a creatinine level of less than 1.6 mg/dL; as stated in the text [1] , no patients had an arterial partial pressure of oxygen/ fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio of less than 300. Th e high median and inter quartile values for the SOFA scores would be possible only in the presence of severe neurological or hemo dynamic dys func tion in the majority of the patients; this point, there fore, requires further explanation. Moreover, at least 50% of the patients had lactate levels of higher than 3.7 mmol/L, and this suggests that many patients already had signs of hypoperfusion (that is, severe sepsis) at inclusion. We believe that this paper needs more clarity as all of the above aspects are relevant for readers of Critical Care. INTERSEPT study has several limitations. As clearly mentioned in the paper [1] , only fi ve centers included patients. Th e primary center contributed 86% of them and such information was always available to all investigators on the trial website. Th e primary reason why some institutions included patients while some did not is simple and was shared with all other investigators during the trial: the adoption of a more proactive approach. Centers that manage to include patients searched for them in the emergency and general wards. If a patient *Correspondence: fmachado.dcir@epm.br 1 Hospital Sao Paulo, Anesthesiology and Critical Care Department, Universidade Federal de Sao Paulo, R. Napoleao Barros 715 5a andar, Sao Paulo -SP, Brazil, 04024900 Full list of author information is available at the end of the article was found and if a bed was available, they were transferred to be treated in the intensive care unit. Th is demands an extraordinary amount of time and eff ort, and many centers decided not to follow this strategy. But there are other reasons for the lack of inclusion in other centers: It was impossible to blind the diet in two of the institutions, because their nutrition was prepared by independent companies located outside the hospital. More importantly, some institutions were clearly not interested in participating in the trial; we have recorded that fi ve centers did not use their secret log-in/password a single time, not even to receive the electronic Clinical Research Forum mandatory online training. We want to highlight that all necessary care was taken to ensure the highest standards of quality and strict protocol adherence for the included patients. After its conclusion, the study was submitted to an extensive audit, and all study records, databases, institutional review board approvals, diet controls, written informed consents, and original medical records of the primary center were checked by independent auditors without any interference of the investigators, and only after this quality-control audit was the study submitted for publication. In the text of Machado, there is an assumption that the 'the high median and interquartile values for the SOFA score would be possible only in the presence of severe neurological and hemodynamic dysfunction in the majority of the patients' and this assumption is incorrect. All patients, indeed, did have a PaO 2 /FiO 2 ratio of above 300, but many had a PaO 2 /FiO 2 ratio of between 400 and 300, representing 1 SOFA point. Similarly, a bilirubin level of 1.3 to 1.4 mg/dL and a platelet count of 144 to 149 × 10 9 cells per liter do represent 1 SOFA point. In regard to lactate levels of included patients, please see Table 2 [1] and observe that the levels are still below the limit considered for metabolic failure. Finally, many included patients were older patients suff ering from stroke and concomitant pneumonia, and this obviously means that they have some SOFA points in their neurologic evaluation. Th is study, like many others, does have several limitations, including the fact that care should be taken to extrapolate the fi ndings to the overall population of patients with early sepsis. However, we believe that the true value of the INTERSEPT study is to serve as guide for future trials, including trials of a larger population of patients to validate the results of the present study.
